Hospital Injectable Products · LP-189
Hydrocortisone Powder for injection
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-189Hospital Injectable Products
- Generic identity
- HydrocortisonePowder for injection
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-189
- Generic ingredient
- Hydrocortisone
- Dosage form
- Powder for injection
- Proposed strength
- 100 mg vial
- Proposed pack
- Vial; carton 10 vials
- Portfolio category
- Hospital Injectable Products
About Hydrocortisone
Hydrocortisone is a glucocorticoid with additional mineralocorticoid activity. Injectable products are used in defined acute or specialist settings, including situations requiring cortisol replacement. They differ from skin creams, oral replacement tablets and other corticosteroid injections. The salt and formulation influence preparation and routes, so a powder-vial description alone does not establish complete pharmaceutical characteristics.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Acute adrenal insufficiency is a time-sensitive medical condition requiring an appropriate emergency pathway. Other systemic hydrocortisone uses depend on diagnosis-specific guidance. Clinical teams assess haemodynamic status, infection, glucose and other relevant findings. The catalogue provides high-level ingredient information only; it does not supply an adrenal-crisis regimen, an allergy-treatment algorithm or proof that any listed indication has been approved for this candidate.
Important safety considerations
Hyperglycaemia, fluid retention, changes in blood pressure, infection risk and psychiatric effects can occur. Repeated systemic exposure can suppress adrenal function and affect bones, eyes and other organs. Severe allergy to the injection or its excipients is possible. Review diabetes, infection and relevant interactions. Corticosteroids do not replace first-line emergency management of anaphylaxis. Any stopping or replacement plan must reflect the clinical condition and prior exposure.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The source specifies powder for injection, without confirming the hydrocortisone salt. The correct diluent, final concentration, authorized routes and post-reconstitution period require the exact product label. A salt-specific comparator must be chosen only after identity is verified.
Professional preparation must follow the authorized label and local aseptic procedures. Confirm the correct container, concentration, route and expiry before use. Storage, transport, dilution compatibility and any period after opening or reconstitution require product-specific evidence; this page does not establish them.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Confirm the acute or specialist indication, precise formulation, relevant metabolic and infection risks, and monitoring. Use the locally authorized label and clinical protocol.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Hydrocortisone
- Dosage form / presentation
- Powder for injection
- Catalogue strength
- 100 mg vial
- Catalogue pack
- Vial; carton 10 vials
- Portfolio category
- Hospital Injectable Products
Layer 02
Unresolved product-specific fields
- The catalogue establishes hydrocortisone powder for injection at 100 mg/vial but does not identify the hydrocortisone salt, authorised route, diluent, final concentration or post-reconstitution stability.
- Do not assume hydrocortisone sodium succinate or transfer salt-specific preparation instructions from an external comparator.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- MedlinePlus: Hydrocortisone Injectiongovernment-hosted medicine monograph
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Sterile product specification confirming exact active chemical form, concentration or vial content, container/fill, authorised route(s), excipients/preservatives and preparation/compatibility controls.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-189, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-189.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.